Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Comfort Systems USA Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.42 (market cap $5.07B), while Comfort Systems USA Inc trades at $1,746.89 (market cap $59.41B). The key difference: Comfort Systems USA Inc is far larger — about 11.7× ACADIA Pharmaceuticals Inc.'s market cap, and Comfort Systems USA Inc pays a 0.21% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FIX | |
|---|---|---|
Market Cap | $5.07B | $59.41B |
Sector | Health | Technology |
52-Week High | $29.41 | $2.07K |
52-Week Low | $20.06 | $680.86 |
Enterprise Value | $4.19B | $57.88B |
Dividend Yield | — | 0.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Comfort Systems USA (FIX) trades at $1,750.90, up 4.54% with strong earnings momentum as Q2 2026 EPS of $12.53 beat expectations by 20%. The stock shows bearish technical signals but maintains robust fundamentals with 55.29% ROE and record backlog driven by data center demand. Recent news highlights margin expansion and institutional position adjustments.
Outlook remains positive given analyst consensus price target of $2,170 (24% upside), though premium valuation (P/E 41.55) and execution risks warrant caution. Key opportunities include AI-driven data center growth, while risks involve capacity constraints and market volatility near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
